Top News
FEATURED
Talazoparib May Improve PFS
Oral treatment with talazoparib improved progression-free survival and some quality of life measures compared with standard chemotherapy.
PARP Inhibitor Resistance, Certain Mutations Prognostic
Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alternative treatments.
Osimertinib Compared With Standard EGFR-TKIs
A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows "impressive" clinical activity in the CNS.
Ask the Experts: NSCLC
Cancer Therapy Advisor asked 2 experts to weigh in on recommended treatment modalities for patients with non-small cell lung cancer.
Ask the Experts: STS Clinical Insights
Cancer Therapy Advisor asked 2 experts to weigh in on the latest clinical insights into soft tissue sarcoma.
Ask the Experts: Waldenström Macroglobulinemia
Cancer Therapy Advisor asked 3 experts to weigh in on recommended treatment modalities for patients with Waldenström macroglobulinemia.
Looking for a Job?
Access our job board to view over 1,200 job openings throughout the US.
Treatment Regimens
A full listing of cancer treatment and drug information is available to access.
Latest Features
Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer
Oral treatment with talazoparib improved progression-free survival and some quality of life measures compared with standard chemotherapy.
BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alternative treatments.
"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows "impressive" clinical activity in the CNS.
Genetic Counseling Recommended for Advanced Prostate Cancer
A new white paper emphasizes the benefits of germline testing.
Cancer Chemotherapeutics in Rheumatoid Arthritis: A Complex Connection
Research is still needed to explore the association between cancer chemotherapeutics and rheumatoid arthritis.
Editorial Advisory Board
E. David Crawford, MD
Jeffrey M. Farma, MD
Digital Issue
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer
- Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL